D1 Capital Partners led an $81m funding round in Rapid Micro Biosystems, a provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, with participation from BlackRock, T. Rowe Price Associates, Adage Capital Management, Sunley House Capital Management, and CaaS Capital Management. "This new investment will enable continued acceleration of our company’s growth as we help global drug manufacturers significantly improve data integrity, reduce risk, accelerate decision making and improve the operational efficiency of their quality control processes. We are excited about the support of our new investors, who share our mission of improving the robustness and safety of the global pharmaceutical manufacturing ecosystem," Robert Spignesi, Rapid Micro Biosystems President and CEO.